User profiles for Juan P. Rocca

JUAN P. ROCCA, MD, MHA, FACS

Associate Professor of Surgery. Albert Einstein College of Medicine.
Verified email at montefiore.org
Cited by 2037

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways

…, M Mokrzycki, H Rominieki, JA Graham, JP Rocca… - Nature …, 2019 - nature.com
The molecular and cellular processes that lead to renal damage and to the heterogeneity of
lupus nephritis (LN) are not well understood. We applied single-cell RNA sequencing (…

Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation

ME Facciuto, B Koneru, JP Rocca, DC Wolf… - Annals of surgical …, 2008 - Springer
Background There is no clear consensus regarding the best treatment strategy for patients
with advanced hepatocellular carcinoma (HCC). Methods Patients with cirrhosis and HCC …

[HTML][HTML] Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer

…, J Hyun, S Khan, M Wood, B Samstein, JP Rocca… - Oncogene, 2023 - nature.com
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting
presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite …

Exploring the usage of a mobile phone application in transplanted patients to encourage medication compliance and education

…, A Rizzo, N Hayde, AC Watkins, JP Rocca… - The American Journal of …, 2017 - Elsevier
Background Medication non-adherence in transplant patients is a grave problem that results
in increased rejection episodes, graft loss and significant morbidity. Methods The efficacy of …

Transplant surgery enters a new era: increasing immunosuppressive medication adherence through mobile apps and smart watches

D Levine, J Torabi, K Choinski, JP Rocca… - The American Journal of …, 2019 - Elsevier
The high rate of immunosuppressive medication non-adherence in transplant recipients
demands the search for a solution that targets modifiable risk factors and incorporates mobile …

Commercial insurance delays direct‐acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients

J Torabi, JP Rocca, M Ajaimy, J Melvin… - Transplant Infectious …, 2021 - Wiley Online Library
Introduction The advent of direct‐acting antivirals (DAAs) has created an avenue for
transplantation of hepatitis C virus (HCV)‐infected donors into uninfected recipients (D+/R−). The …

The abdominal transplant surgery workforce: current state and future trends

FM Kaldas, JP Rocca, CS Bhati, N Duan… - Clinical …, 2019 - Wiley Online Library
Transplant surgical workforce concerns have arisen in the last 5 years as reflected in
challenges securing job opportunities for new fellows. The present survey was designed by the …

Recanalized umbilical vein conduit for meso-Rex bypass in extrahepatic portal vein obstruction

…, MI Rodriguez-Davalos, MK Singh, JP Rocca… - Surgery, 2009 - Elsevier
BACKGROUND: Meso-Rex bypass is used to treat patients with clinically important extrahepatic
portal vein obstruction (EHPVO). Usually, an autologous left internal jugular vein graft is …

Transplantation of viral‐positive hepatitis C‐positive kidneys into uninfected recipients offers an opportunity to increase organ access

…, JF Reinus, MM Kinkhabwala, JP Rocca - Clinical …, 2020 - Wiley Online Library
The advent of direct‐acting antivirals (DAAs) has provided the impetus to transplant kidneys
from hepatitis C virus‐positive donors into uninfected recipients (D+/R−). Thirty D+/R− …

Right hepatectomy for living donation: role of remnant liver volume in predicting hepatic dysfunction and complications

M Facciuto, A Contreras-Saldivar, MK Singh, JP Rocca… - Surgery, 2013 - Elsevier
BACKGROUND: Extensive attention has been placed on remnant liver volume (RLV) above
other factors to ensure donor safety. METHODS: We performed a retrospective review of …